For decades, venture investors have struggled with the a basic business-model problem: how to make money from companies that, to create a product, require years, hundreds of millions of dollars, widely varied kinds of management expertise, and lucky sevens on dozens of scientific and commercial bets.
The answer, broadly speaking, is translational medicine. In any event, that’s the latest business proposal from Versant Ventures.







